Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines
BACKGROUND: In 2022, the WHO announced that the 6-month BPaL/M regimen should be used for drug-resistant TB (DR-TB). We estimate the patient and provider costs of BPaL compared to current standard-of-care treatment in the Philippines.METHODS: Patients on BPaL under operational research, or 9–11-mont...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-06-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000006/art00002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592300826427392 |
|---|---|
| author | D. Evans K. Hirasen D.J. Casalme M.T. Gler A. Gupta S. Juneja |
| author_facet | D. Evans K. Hirasen D.J. Casalme M.T. Gler A. Gupta S. Juneja |
| author_sort | D. Evans |
| collection | DOAJ |
| description | BACKGROUND: In 2022, the WHO announced that the 6-month BPaL/M regimen should be used for drug-resistant TB (DR-TB). We estimate the patient and provider costs of BPaL compared to current standard-of-care treatment in the Philippines.METHODS: Patients on BPaL under operational research, or 9–11-month standard short oral regimen (SSOR) and 18–21-month standard long oral regimen (SLOR) under programmatic conditions were interviewed using the WHO cross-sectional TB patient cost tool. Provider costs were assessed through a bottom-up and top-down costing analysis.RESULTS: Total patient costs per treatment episode were lowest with BPaL (USD518.0) and increased with use of SSOR (USD825.8) and SLOR (USD1,023.0). Total provider costs per successful treatment were lowest with BPaL (USD1,994.5) and increased with SSOR (USD3,121.5) and SLOR (USD10,032.4). Compared to SSOR, BPaL treatment was cost-effective at even the lowest willingness to pay threshold. As expected, SLOR was the costliest and least effective regimen.CONCLUSIONS: Costs incurred by patients on BPaL were 37% (95% CI 22–56) less than SSOR and 50% (95% CI 32–68) less than SLOR, while providers could save 36% (95% CI 21–56) to 80% (95% CI 64–93) per successful treatment, respectively. The study shows that treatment of DR-TB with BPaL was cost-saving for patients and cost-effective for the health system. |
| format | Article |
| id | doaj-art-a1b662e6baa34942b03c3609f5500c7c |
| institution | Kabale University |
| issn | 3005-7590 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-a1b662e6baa34942b03c3609f5500c7c2025-01-21T10:44:17ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-06-011624224910.5588/ijtldopen.24.00942Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the PhilippinesD. Evans0K. Hirasen1D.J. Casalme2M.T. Gler3A. Gupta4S. Juneja5Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,TB-HIV Innovations and Research Foundation,TB-HIV Innovations and Research Foundation,TB Alliance, New York, NY, USATB Alliance, New York, NY, USABACKGROUND: In 2022, the WHO announced that the 6-month BPaL/M regimen should be used for drug-resistant TB (DR-TB). We estimate the patient and provider costs of BPaL compared to current standard-of-care treatment in the Philippines.METHODS: Patients on BPaL under operational research, or 9–11-month standard short oral regimen (SSOR) and 18–21-month standard long oral regimen (SLOR) under programmatic conditions were interviewed using the WHO cross-sectional TB patient cost tool. Provider costs were assessed through a bottom-up and top-down costing analysis.RESULTS: Total patient costs per treatment episode were lowest with BPaL (USD518.0) and increased with use of SSOR (USD825.8) and SLOR (USD1,023.0). Total provider costs per successful treatment were lowest with BPaL (USD1,994.5) and increased with SSOR (USD3,121.5) and SLOR (USD10,032.4). Compared to SSOR, BPaL treatment was cost-effective at even the lowest willingness to pay threshold. As expected, SLOR was the costliest and least effective regimen.CONCLUSIONS: Costs incurred by patients on BPaL were 37% (95% CI 22–56) less than SSOR and 50% (95% CI 32–68) less than SLOR, while providers could save 36% (95% CI 21–56) to 80% (95% CI 64–93) per successful treatment, respectively. The study shows that treatment of DR-TB with BPaL was cost-saving for patients and cost-effective for the health system.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000006/art00002bedaquilinepretomanidlinezolideconomic evaluationcost analysis |
| spellingShingle | D. Evans K. Hirasen D.J. Casalme M.T. Gler A. Gupta S. Juneja Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines IJTLD Open bedaquiline pretomanid linezolid economic evaluation cost analysis |
| title | Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines |
| title_full | Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines |
| title_fullStr | Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines |
| title_full_unstemmed | Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines |
| title_short | Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines |
| title_sort | cost and cost effectiveness of bpal regimen used in drug resistant tb treatment in the philippines |
| topic | bedaquiline pretomanid linezolid economic evaluation cost analysis |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000006/art00002 |
| work_keys_str_mv | AT devans costandcosteffectivenessofbpalregimenusedindrugresistanttbtreatmentinthephilippines AT khirasen costandcosteffectivenessofbpalregimenusedindrugresistanttbtreatmentinthephilippines AT djcasalme costandcosteffectivenessofbpalregimenusedindrugresistanttbtreatmentinthephilippines AT mtgler costandcosteffectivenessofbpalregimenusedindrugresistanttbtreatmentinthephilippines AT agupta costandcosteffectivenessofbpalregimenusedindrugresistanttbtreatmentinthephilippines AT sjuneja costandcosteffectivenessofbpalregimenusedindrugresistanttbtreatmentinthephilippines |